Article Text

Download PDFPDF
The benefits of diagnostic ERCP in autoimmune pancreatitis
  1. Markus M Lerch,
  2. Julia Mayerle
  1. Department of Medicine A, Greifswald University Hospital, Greifswald, Germany
  1. Correspondence to Dr Markus M Lerch, Department of Medicine A, Greifswald University Hospital, Friedrich-Loeffler-Str. 23A, 17475 Greifswald, Germany; lerch{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Autoimmune pancreatitis (AIP) is a puzzling disease. Although its cardinal features were first reported in Europe,1 it seemed, for a long time an Asian phenomenon which many Western clinicians felt they could largely ignore.2 3 As more case series were reported from Europe and America it became increasingly clear that AIP affects patients from many ethnic backgrounds. AIP shares features with two other disorders of the pancreas from which a distinction is critical and determines appropriate treatment. The first is chronic pancreatitis of either the environmentally induced (alcohol, tobacco smoke) or the hereditary variety.4–6 The most important difference in terms of treatment, prognosis and, to a lesser degree, diagnosis is that AIP rapidly responds to the administration of steroids7 and other varieties of pancreatitis do not.

Reports from Japan suggesting that AIP can be distinguished from chronic pancreatitis by serological markers alone, most prominently serum IgG4 levels,8 were greeted with great enthusiasm. Unfortunately, clinical chemistry was quickly found to be much less reliable in Caucasian patients.9 The reason behind this difference lies in two subtypes of AIP with different prevalence in Europe and Asia. The first subtype, and by far the most common in Asia, has recently been termed lymphoplasmacytic sclerosing pancreatitis (LPSP or type I AIP) according to its histological features.10 It is commonly associated with immunological changes such as elevated IgG4 serum levels or various autoantibodies of lesser diagnostic value. A second disease variety named idiopathic duct-centric pancreatitis (IDCP or type II AIP), that barely exists in Japan, accounts for a significant number of Caucasian patients, displays often none of the immunological changes and is characterised histologically by granulocytic epithelial lesions. …

View Full Text


  • Linked articles 207951.

  • Funding The author's own work is supported by the Alfried-Krupp-von-Bohlen-und-Hallbach-Foundation (Graduate Schools Tumour Biology and Free Radical Biology), the Deutsche Krebshilfe/ Dr. Mildred-Scheel-Stiftung (109102), the Deutsche Forschungsgemeinschaft (DFG GRK840-E3/E4, MA 4115/1-2/3, NI 1297/1-1), the Federal Ministry of Education and Research (BMBF GANI-MED 03152061A and BMBF 0314107) and the European Union (EU-FP-7: EPC-TM and EU-FP7-REGPOT-2010-1).

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Commissioned; externally peer reviewed.

Linked Articles

  • Pancreas
    Aravind Sugumar Michael J Levy Terumi Kamisawa George J M Webster Myung-Hwan Kim Felicity Enders Zahir Amin Todd H Baron Mike H Chapman Nicholas I Church Jonathan E Clain Naoto Egawa Gavin J Johnson Kazuichi Okazaki Randall K Pearson Stephen P Pereira Bret T Petersen Samantha Read Raghuwansh P Sah Neomal S Sandanayake Naoki Takahashi Mark D Topazian Kazushige Uchida Santhi Swaroop Vege Suresh T Chari